Compass Pathways: A Calculated Long Ahead of an Imminent FDA Crossroads
Compass Pathways (CMPS) is a volatile, binary biotech with clear upside if regulatory momentum continues. With a market cap of ~$1.65B, roughly $3.03 in reported cash per share and bullish technicals, I recommend a mid-term long trade ahead of an upcoming FDA verdict. Entry, stop and target are provided with rationale and risk controls.